本文選題：慢性萎縮性胃炎 + 健脾清熱活血方�。� 參考：《南京中醫(yī)藥大學(xué)》2017年碩士論文

【摘要】：研究目的通過(guò)運(yùn)用導(dǎo)師自擬健脾清熱活血方與胃復(fù)春片進(jìn)行隨機(jī)對(duì)照治療CAG患者,觀察其臨床療效、胃黏膜內(nèi)鏡表現(xiàn)及病理組織學(xué)的改善情況,客觀評(píng)價(jià)健脾清熱活血方的療效,以推廣其臨床應(yīng)用。研究方法選擇60例經(jīng)胃鏡診斷為CAG的患者,隨機(jī)分為兩組,每組各30例,治療組予健脾清熱活血方口服,對(duì)照組予胃復(fù)春片口服,療程6個(gè)月。治療結(jié)束后復(fù)查胃鏡,觀察兩組患者的治療前后癥狀積分、胃鏡及病理組織學(xué)等變化情況,數(shù)據(jù)整理后進(jìn)行統(tǒng)計(jì)學(xué)分析。研究結(jié)果1.中醫(yī)證侯總有效率:治療組為93.33%,對(duì)照組為66.67%,差別有統(tǒng)計(jì)學(xué)意義(P0.05)。2.臨床各癥狀方面:治療組對(duì)胃脹、胃痛、噯氣、口苦口干的改善程度明顯優(yōu)于對(duì)照組(P0.01);對(duì)食少納呆、吐酸嘈雜、痛有定處、乏力、大便不暢、大便稀溏、大便干燥等癥狀的緩解治療組優(yōu)于對(duì)照組(P0.05)。3.胃黏膜內(nèi)鏡表現(xiàn)及病理組織學(xué)方面:治療組在改善萎縮、腸化、活動(dòng)性炎癥、慢性炎癥方面優(yōu)于對(duì)照組(P0.05),而在抗Hp感染、改善糜爛、膽汁反流方面兩組療效無(wú)明顯差異(P0.05)。治療組胃鏡及病理總有效率為90.00%,對(duì)照組為63.33%,治療組在改善患者胃鏡及病理組織學(xué)方面優(yōu)于對(duì)照組(P0.05)。研究結(jié)論通過(guò)兩組病例的比較,在癥狀積分、胃黏膜內(nèi)鏡表現(xiàn)及病理組織學(xué)方面,治療組優(yōu)于對(duì)照組,且部分患者的萎縮和腸化得以逆轉(zhuǎn)。由此可見(jiàn),健脾清熱活血方在改善CAG患者臨床癥狀、胃鏡及病理組織學(xué)上有較好的療效,且安全性好,治療過(guò)程中未出現(xiàn)不良反應(yīng)。
[Abstract]:Objective to observe the clinical efficacy, endoscopic manifestations and histopathological improvement of CAG patients by using self-made Jianpi Qingre Huoxue recipe and Weifuchun tablet.Objective to evaluate the curative effect of Jianpi Qingre Huoxue recipe in order to popularize its clinical application.Methods 60 patients with CAG diagnosed by gastroscopy were randomly divided into two groups: 30 cases in each group. The treatment group was treated with Jianpi Qingre Huoxue recipe and the control group was treated with Weifuchun tablet for 6 months.After the treatment, the symptom score, gastroscope and histopathology of the two groups were observed, and the data were analyzed statistically.Results 1.The total effective rate of Hou in TCM syndrome was 93.33 in the treatment group and 66.67 in the control group.Clinical symptoms: the improvement of stomach distension, stomachache, belching and dry mouth in the treatment group was obviously better than that in the control group (P 0.01);The relief of stool dryness in the treatment group was better than that in the control group (P 0.05. 3).The endoscopic manifestations and histopathology of gastric mucosa in the treatment group were better than that in the control group in improving atrophy, intestinal metaplasia, active inflammation and chronic inflammation, but there was no significant difference between the two groups in anti-HP infection, improving erosion and bile reflux.The total effective rate of gastroscope and pathology was 90.00g in the treatment group and 63.33g in the control group. The treatment group was superior to the control group in improving the gastroscope and histopathology.Conclusion compared with the two groups, the treatment group is superior to the control group in terms of symptom score, endoscopic manifestations of gastric mucosa and histopathology, and the atrophy and intestinal metaplasia of some patients can be reversed.It can be seen that Jianpi Qingre Huoxue recipe can improve the clinical symptoms gastroscopy and histopathology of patients with CAG and has good safety and no adverse reaction in the course of treatment.
【學(xué)位授予單位】：南京中醫(yī)藥大學(xué)
【學(xué)位級(jí)別】：碩士
【學(xué)位授予年份】：2017
【分類號(hào)】：R259

【參考文獻(xiàn)】

相關(guān)期刊論文 前10條

1 董佳月;王黎明;丁進(jìn);;雙歧桿菌制劑應(yīng)用于幽門螺桿菌感染患者治療的Meta分析[J];中國(guó)生化藥物雜志;2016年04期

2 李賀元;羅曉韻;安云;;清熱祛濕法治療脾胃濕熱型Hp相關(guān)胃炎[J];光明中醫(yī);2016年06期

3 徐明芬;;辨證治療慢性萎縮性胃炎56例[J];實(shí)用中醫(yī)藥雜志;2016年01期

4 陳美清;李明春;;引起慢性萎縮性胃炎復(fù)發(fā)的危險(xiǎn)因素分析[J];世界最新醫(yī)學(xué)信息文摘;2015年94期

5 馬善美;陳本華;;半夏瀉心湯聯(lián)合埃索美拉唑治療慢性萎縮性胃炎的臨床療效觀察[J];世界中醫(yī)藥;2015年10期

6 劉文忠;;“幽門螺桿菌胃炎京都全球共識(shí)”解讀[J];胃腸病學(xué);2015年08期

7 劉俊杰;張紅燕;張鳳梅;劉艷玲;;慢性萎縮性胃炎患者的消化內(nèi)科臨床治療體會(huì)[J];中國(guó)醫(yī)藥指南;2015年13期

8 李海華;青梅;于娟;梁帥杰;;甘草的研究進(jìn)展[J];內(nèi)蒙古醫(yī)科大學(xué)學(xué)報(bào);2015年02期

9 劉會(huì)民;趙敏杰;;太子參臨床應(yīng)用及研究進(jìn)展[J];中國(guó)醫(yī)院用藥評(píng)價(jià)與分析;2015年03期

10 游昕;熊大國(guó);郭志斌;商友劍;;茯苓多種化學(xué)成分及藥理作用的研究進(jìn)展[J];安徽農(nóng)業(yè)科學(xué);2015年02期

，

本文編號(hào)：1745215